Ipsen S.A. (IPSEY) Stock Price & Analysis
Ipsen S.A. (IPSEY) — price $45.12 (-3.61%), as of the Nov 19, 2026 trading session; market cap $14.9B.
Educational signal · not a buy or sell recommendation · How to read this
Ipsen S.A. · IPSEY · Healthcare · Drug Manufacturers - Specialty & Generic
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $45.12 | |
| Change on the day | -3.61% | |
| 52-week range | $34.34–$51.10 | |
| Market capitalisation | $14.9B | — |
| Price / earnings (trailing) | 26.47 | |
| Shares traded on the day | 1 | |
| Beta (volatility vs the S&P 500) | 0.32 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Ipsen (IPSEY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Ipsen (IPSEY), and what does it report?
Short answer
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Healthcare / Drug Manufacturers Specialty & Generic Headquarters: 70 rue Balard, Paris, IF, 75015, FR. It employs 5,535 people and is led by David G. Loew. In Q2 FY2026 it reported revenue of €2.30B and net income of €403M. The market values it at $14.9B.
What do the latest results show for Ipsen (IPSEY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of €2.30B. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | €2.30B | €403M | €1.22 (diluted) |
| Q4 FY2025 | €1.84B | €109M | €0.28 (diluted) |
| Q2 FY2025 | €1.94B | €334M | €1.00 (diluted) |
| Q4 FY2024 | €1.82B | €114M | €0.34 (diluted) |
What are the financial strengths and risks for Ipsen (IPSEY)?
Short answer · as of
The distress and quality screens read Altman Z 13.67 · Piotroski F 6. Trailing ratios: ROE 11.3% · ROA 6.9% · current ratio 1.97 · earnings yield 3.7% · free-cash-flow yield 8.9%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IPSEY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IPSEY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Ipsen (IPSEY)?
IPSEY Healthcare Stock FAQ
These answers are editorial: 1 of these 8 answers is drawn from the IPSEY research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is IPSEY a good stock to buy?
Stock Expert AI does not rate IPSEY buy, sell or hold. Ipsen S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IPSEY stock price today?
The last price recorded for Ipsen S.A. (IPSEY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for IPSEY?
The main risks for Ipsen S.A. include increasing competition from generic drug manufacturers, which could erode sales of its established products. The uncertainty of clinical trial outcomes poses a risk to its pipeline of new therapies.
What are the key factors to evaluate for IPSEY?
Evaluate IPSEY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Strategic acquisitions to expand product portfolio: Ipsen can pursue strategic acquisitions to expand its product portfolio and gain access to new therapeutic areas or technologies. Not financial advice.
How frequently does IPSEY data refresh on this page?
IPSEY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IPSEY's recent stock price performance?
Ipsen S.A. (IPSEY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio in specialty care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IPSEY overvalued or undervalued right now?
The trailing P/E of Ipsen S.A. (IPSEY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IPSEY before investing?
Before investing in Ipsen S.A. (IPSEY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com